• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Natera Inc.

    12/5/25 8:34:41 AM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    S-8 1 tm2532406d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on December 5, 2025

     

    Registration No. 333-                   

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

     

    NATERA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware
    (State or Other Jurisdiction of Incorporation or
    Organization)

    01-0894487

    (I.R.S. Employer Identification No.)

     

    13011 McCallen Pass

    Building A, Suite 100

    Austin, TX 78753

     

    (650) 980-9190

    (Address of Principal Executive Offices, Zip Code)

     

    Foresight Diagnostics Inc. 2020 Equity Incentive Plan

    (Full title of the plan)

     

    Michael Brophy

    Chief Financial Officer

    Natera, Inc.

    13011 McCallen Pass

    Building A, Suite 100

    Austin, TX 78753

    (650) 980-9190

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    With a copy to:

     

    Gina Hancock

    Gibson, Dunn & Crutcher LLP

    2001 Ross Avenue, Suite 2100

    Dallas, TX 75201-2923

    (214) 698-3100

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
           
    Non-accelerated filer ¨ Smaller reporting company ¨
           
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On December 4, 2025 (the “Closing Date”), Natera, Inc., a Delaware corporation (the “Registrant”), completed a business combination (the “Merger”) with Foresight Diagnostics Inc., a Delaware corporation (“Foresight”), pursuant to an Agreement and Plan of Merger, dated as of October 10, 2025, by and among the Registrant, Falcon Acquisition Sub, Inc., Foresight and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the initial representative of the equityholders of Foresight.

     

    This Registration Statement on Form S-8 is being filed by the Registrant to register 88,126 shares of the Registrant’s common stock, par value $0.0001 per share (the “Common Stock”), issuable under the Foresight Diagnostics Inc. 2020 Equity Incentive Plan pursuant to outstanding stock options to purchase shares of Foresight common stock that were assumed by the Registrant and converted into stock options to purchase shares of Common Stock in connection with the Merger.

     

     

     

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1.Plan Information.

     

    The documents containing the information specified in Part I of Form S-8 will be delivered to the grantee as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the instructions to Part I of Form S-8, such documents are not being filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

     

     

     

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.Incorporation of Certain Documents by Reference.

     

    The following documents, which have previously been filed by the Registrant with the Commission pursuant to the Securities Act and pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference herein and shall be deemed to be a part hereof:

     

    (a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Annual Report”), filed with the SEC on February 28, 2025;

     

    (b)the Registrant’s Quarterly Reports on Form 10-Q for the quarters ended on March 31, 2025, June 30, 2025, and September 30, 2025;

     

    (c)the Registrant’s Current Reports on Form 8-K filed with the Commission on March 12, 2025, June 18, 2025, and December 5, 2025; and

     

    (d)the description of the Registrant’s common stock contained in the Registrant’s Description of Capital Stock, filed as Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 26, 2021, including any amendments or reports filed for the purpose of updating such description.

     

    In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

     

    Any statement, including financial statements, contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or therein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 4.Description of Securities.

     

    Not applicable.

     

    Item 5.Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6.Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.

     

    As permitted by the Delaware General Corporation Law, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions relating to the limitation of liability and indemnification of directors and officers. The amended and restated certificate of incorporation provides that our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability:

     

    ·for any breach of the director’s duty of loyalty to us or our stockholders;

    ·for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

    ·in respect of unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

    ·for any transaction from which the director derives any improper personal benefit.

     

    Our amended and restated certificate of incorporation also provides that if Delaware law is amended after the approval by our stockholders of the certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law.

     

    Our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law, as it now exists or may in the future be amended, against all expenses and liabilities reasonably incurred in connection with their service for or on our behalf. Our amended and restated bylaws provide that we shall advance the expenses incurred by a director or officer in advance of the final disposition of an action or proceeding, and permit us to secure insurance on behalf of any director, officer, employee, or other enterprise agent for any liability arising out of his action in that capacity, whether or not Delaware law would otherwise permit indemnification.

     

    We have entered into indemnification agreements with each of our directors and executive officers and certain other key employees. The form of agreement provides that we will indemnify each of our directors, executive officers and such other key employees against any and all expenses incurred by that director, executive officer, or other key employee because of his status as one of our directors, executive officers or other key employees, to the fullest extent permitted by Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws. In addition, the form agreement provides that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors, executive officers and other key employees in connection with a legal proceeding.

     

    We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Exchange Act that might be incurred by any director or officer in his capacity as such.

     

     

     

     

    Item 7.Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8.Exhibits.

     

    Exhibit       Incorporated by Reference   Filed
    No.   Exhibit Description   Form   Number   Date   Herewith
    4.1   Amended and Restated Certificate of the Incorporation of the Registrant   8-K   3.1   07/09/2015    
    4.2   Amended and Restated Bylaws of the Registrant Inc.   10-Q   3.1   11/05/2021    
    4.3   Form of Common Stock Certificate   S-1/A   4.1   06/22/2015    
    5.1   Opinion of Gibson, Dunn & Crutcher LLP               X
    23.1   Consent of Independent Registered Public Accounting Firm               X
    23.2   Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1)               X
    24.1   Power of Attorney (included on the signature page to this Registration Statement)               X
    99.1   Foresight Diagnostics Inc. 2020 Equity Incentive Plan and Form of Stock Option Agreement               X
    107.1   Filing Fee Table               X

     

    Item 9.Undertakings.

     

    (a)           The undersigned Registrant hereby undertakes:

     

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

     

     

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas on this 5th day of December, 2025.

     

      NATERA, INC.
         
      By: /s/ Michael Brophy
      Name: Michael Brophy
      Title: Chief Financial Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven Chapman and Michael Brophy and each of them, the individual’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the date set forth below.

     

    Name   Title   Date
             
    /s/ Steven Chapman   Chief Executive Officer, President and Director    
    Steven Chapman   (Principal Executive Officer)   December 5, 2025
             
    /s/ Michael Brophy   Chief Financial Officer    
    Michael Brophy   (Principal Financial and Accounting Officer)   December 5, 2025
             
    /s/ Matthew Rabinowitz        
    Matthew Rabinowitz   Executive Chairman   December 5, 2025
             
    /s/ Jonathan Sheena        
    Jonathan Sheena   Founder and Director   December 5, 2025
             
    /s/ Roy Baynes        
    Roy Baynes   Director   December 5, 2025
             
    /s/ Monica Bertagnolli        
    Monica Bertagnolli   Director   December 5, 2025
             
    /s/ Roelof Botha        
    Roelof Botha   Director   December 5, 2025
             
    /s/ Rowan Chapman        
    Rowan Chapman   Director   December 5, 2025
             
    /s/ Gail Marcus        
    Gail Marcus   Director   December 5, 2025
             
    /s/ Herm Rosenman        
    Herm Rosenman   Director   December 5, 2025
             
    /s/ Ruth Williams-Brinkley        
    Ruth Williams-Brinkley   Director   December 5, 2025

     

     

     

    Get the next $NTRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    12/2/2025$265.00Overweight
    Morgan Stanley
    10/27/2025$172.00Underperform → Neutral
    BNP Paribas Exane
    9/22/2025$175.00Equal Weight
    Wells Fargo
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $NTRA
    SEC Filings

    View All

    SEC Form S-8 filed by Natera Inc.

    S-8 - Natera, Inc. (0001604821) (Filer)

    12/5/25 8:34:41 AM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form S-3 filed by Natera Inc.

    S-3 - Natera, Inc. (0001604821) (Filer)

    12/5/25 8:28:31 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Natera, Inc. (0001604821) (Filer)

    12/5/25 8:01:04 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Natera Inc.

    4 - Natera, Inc. (0001604821) (Issuer)

    12/3/25 8:35:04 PM ET
    $NTRA
    Medical Specialities
    Health Care

    PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $714,459 worth of shares (3,000 units at $238.15), decreasing direct ownership by 3% to 109,061 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    12/3/25 8:35:07 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Director Botha Roelof sold $17,708,936 worth of shares (75,000 units at $236.12) (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    11/26/25 5:00:41 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Natera with a new price target

    Morgan Stanley resumed coverage of Natera with a rating of Overweight and set a new price target of $265.00

    12/2/25 8:28:19 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Natera from Underperform to Neutral and set a new price target of $172.00

    10/27/25 9:03:32 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Wells Fargo resumed coverage on Natera with a new price target

    Wells Fargo resumed coverage of Natera with a rating of Equal Weight and set a new price target of $175.00

    9/22/25 8:32:15 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Natera Acquires Foresight Diagnostics

    Expands Natera's lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera's portfolio of >500 issued or pending patents Accelerates Natera's expansion into lymphoma, where Foresight has developed a strong clinical position Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company's ci

    12/5/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

    Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies. The datasets include an oral presentation on a retrospective real-world cohort evaluating 144 patient

    12/3/25 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

    Signatera Genome demonstrated 100% sensitivity and specificity in detecting breast cancer recurrence in the surveillance setting Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that at least twelve abstracts highlighting Signatera will be shared at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12. The presentations encompass aggregated data from more than 50,000 patients in real-world evidence and prospective clinical studies, demonstrating the prognostic and predictive power of Signatera across diverse breast cancer subtypes and settings. These include real-world studies of Signatera adoption and clinica

    12/2/25 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Acquires Foresight Diagnostics

    Expands Natera's lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera's portfolio of >500 issued or pending patents Accelerates Natera's expansion into lymphoma, where Foresight has developed a strong clinical position Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company's ci

    12/5/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Reports Third Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period. Generated a gross margin percentage2 of 64.9% in the third quarter of 2025, compared to a gross margin percentage2 of 61.8% in the third quarter of 2024. Processed approximately 893,600 tests in the third quarter of 2025, compared to approximately 775,800 tests in the third quarter of 2024,

    11/6/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report its Third Quarter Results on November 6, 2025

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information Event: Natera's Third Quarter 2025 Financial Results Date: November 6, 2025 Time: 4:30 p.m. ET Live Dial-In: 1-888-770-7321 (Domestic)   1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/822764987

    10/30/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

    Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

    2/23/23 8:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

    AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

    5/24/22 8:03:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care